星太链集团与Scaling Lab订立赞助研究及战略顾问协议

Core Viewpoint - The collaboration between Starry Chain Group and Scaling Lab, a part of Johns Hopkins University, aims to enhance the company's research and development efforts in non-injection diabetes treatments and related metabolic diseases, providing significant scientific and strategic advantages [1][2]. Group 1 - The agreement includes non-clinical and non-regulatory sponsored research on cardiovascular and metabolic diseases, focusing on diabetes and water channel proteins (AQP) [1]. - Dr. Young and his team will provide strategic scientific advisory services to support the development of oral diabetes medications, oral peptide therapies, and drug delivery systems [1]. - The intellectual property generated by Scaling Lab will be owned by Johns Hopkins University, but the company will have preferential and commercially reasonable licensing rights, including priority in global licensing negotiations [1]. Group 2 - The partnership with Johns Hopkins University represents a significant commitment to achieving successful commercialization through high-quality research, enhancing the company's scientific standing and supporting future international collaborations [2]. - The expertise of Scaling Lab in metabolic physiology and diabetes mechanisms will provide a strong scientific foundation for the ongoing development of oral insulin and oral peptide therapies [2]. - The five-year research framework established by the agreement will promote continuous collaboration, knowledge transfer, and talent development, potentially contributing to the company's long-term competitiveness in the global diabetes treatment market [2].